PureHealth Acquires UK's Circle Health for $1.2 Bn to Expand Global Presence

Abu Dhabi's PureHealth acquired UK's Circle Health Group for $1.2 billion, marking an entry into the UK healthcare sector as a part of global expansion.

Abu Dhabi-based PureHealth has acquired the Circle Health Group, the UK's largest independent operator of hospitals in a deal valued at $1.2 billion. With this move, the largest healthcare platform in the Middle East, PureHealth, ventured into the UK market.

This strategic move is a part of PureHealth's global expansion, following previous acquisitions in the US and other international markets. The acquisition includes 100% ownership of Circle Health Group's specialities, such as orthopaedics, oncology, cardiothoracic surgery, and state-of-the-art hospitals, including the UK's first purpose-built rehabilitation facility.

Farhan Malik, founder & MD, PureHealth, said, "This acquisition is more than a global expansion. This move aligns with our vision of pioneering a healthier future for all and underscores our commitment to elevating the global position of Abu Dhabi in the healthcare sector and revolutionising healthcare services globally. We look forward to fostering long-term partnerships within the UK’s healthcare ecosystem."

With this initiative, PureHealth aims to enhance healthcare choices, invest in scientific innovation, and uphold international quality standards, ultimately providing patients in the UAE and the UK with superior medical care.

PureHealth’s Acquisition Spree

In November, last year, PureHealth entered into a strategic partnership with Dell Technologies to leverage Generative Artificial Intelligence (GenAI) in various healthcare services, including early disease detection, medical data analysis, and personalised treatment plans. The collaboration aimed to advance Abu Dhabi’s health ecosystem by combining the resources and technologies of both entities, with the goal of improving health outcomes, ensuring access to advanced medical solutions, and accelerating long-term preparedness and agility.

Recently, PureHealth concluded its acquisition of a minority equity stake in Ardent Health Services, a Nashville-based healthcare provider, in a deal valued at over Dh1.8 billion. This strategic move expanded PureHealth's existing footprint, which already included over 25 hospitals, more than 100 clinics, and more than 160 laboratories in the UAE.

Established in 2016 and headquartered in Abu Dhabi, United Arab Emirates, PureHealth is one of the leading integrated healthcare network in the UAE. With a comprehensive ecosystem covering hospitals, clinics, diagnostics, insurance, pharmacies, health tech, procurement, and more, PureHealth operates both on the ground and in the cloud to advance the Science of Longevity.

PureHealth challenges lifespans and reimagines health spans, boasting 25+ hospitals, 100+ clinics, multiple diagnostic centres, health insurance solutions, pharmacies, health tech, procurement, investments, and more. The company is on a mission to introduce the healthcare of the future from the UAE to the world, with groundbreaking innovations that aim to unlock time for humankind.

Headquartered in London, Circle Health Group stands as the foremost private healthcare provider in the UK and holds the distinction of being the largest private hospital provider.

Founded in 2004, the company underwent a significant transformation in 2019 when it rebranded as Circle Health Group after acquiring BMI Healthcare, a key rival. This strategic move was accompanied by an expansion into the Chinese market, reflecting the company's commitment to global healthcare initiatives.

As of now, Circle Health Group operates under the ownership of PureHealth, an Abu Dhabi-based holding company. Circle Health Group is characterised by a visionary mission to revolutionise healthcare by establishing an ecosystem that takes proactive responsibility for maintaining people's health.

In a similar development, Bristol Myers acquired RayzeBio in a $4.1 billion deal at $62.50 per share, aiming to establish a stronghold in innovative cancer treatments. The strategic move included gaining RayzeBio's clinical-stage radiopharmaceutical therapeutics (RPT) targeting solid tumours like GEP-NETs, small-cell lung cancer, and hepatocellular carcinoma. Bristol also secured RayzeBio's upcoming Indianapolis manufacturing facility, set to commence GMP drug production in H1 2024. This acquisition bolsters Bristol Myers' commitment to advancing cancer therapies through cutting-edge modalities, focusing on delivering targeted radioactive payloads to solid tumour cells.